Home Cart Sign in  
Chemical Structure| 2647530-73-0 Chemical Structure| 2647530-73-0

Structure of Ensitrelvir
CAS No.: 2647530-73-0

Chemical Structure| 2647530-73-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ensitrelvir is an orally active non-covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 13 nM, showing potential against COVID-19.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ensitrelvir

CAS No. :2647530-73-0
Formula : C22H17ClF3N9O2
M.W : 531.88
SMILES Code : N(C=1N(CC2=C(F)C=C(F)C(F)=C2)C(=O)N(CC=3N=CN(C)N3)C(=O)N1)C4=CC=5C(C=C4Cl)=NN(C)C5
MDL No. :N/A
InChI Key :QMPBBNUOBOFBFS-UHFFFAOYSA-N
Pubchem ID :162533924

Safety of Ensitrelvir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Description
Ensitrelvir (S-217622) represents the first orally administered non-covalent, non-peptidic inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 13 nM[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
VeroE6/TMPRSS2 cells 20 μM 8, 16, 24, 32, 40, 48, 56, 72, and 96 h To evaluate the growth of Nsp5-M49L, Nsp5-E166A, and Nsp5-M49L/E166A in vitro with or without ensitrelvir. Results showed that wild-type virus replicated efficiently in VeroE6/TMPRSS2 cells, while 20 μM ensitrelvir completely inhibited wild-type virus replication. Nsp5-M49L and Nsp5-E166A showed slightly delayed growth in the absence of ensitrelvir, while Nsp5-M49L/E166A showed moderate growth delay. In the presence of ensitrelvir, propagation of Nsp5-M49L was severely impaired, Nsp5-E166A propagation was not detected at all, whereas growth of Nsp5-M49L/E166A was less affected. Nat Commun. 2023 Jul 15;14(1):4231
BHK-21 cells 30-100 μM 48-72 hours To select SARS-CoV-2 3CLpro mutations conferring resistance to Ensitrelvir, identifying 39 unique mutations including Y54C, L167F, Q192R, etc. Sci Transl Med. 2023 Jan 11;15(678):eabq7360
Primary human bronchial epithelial cells (HBE cells) 12, 37, 111, 333 nM 72 hours progeny virus titers were under the detection limit at 333 nM or more Sci Transl Med. 2023 Jan 18;15(679):eabq4064
A549-TMPRSS2-ACE2 20, 5, 1.25 μmol/L 48 hours Secondary screening confirmed dose-dependent antiviral activity, 40/168 compounds caused ≥2-log10 viral load reduction. Acta Pharm Sin B. 2024 Sep;14(9):4028-4044
VeroE6 5 μmol/L 72 hours Primary screening for compounds inhibiting SARS-CoV-2 cytopathic effect, 168/50213 compounds showed >60% cell viability. Acta Pharm Sin B. 2024 Sep;14(9):4028-4044
Vero 81 cells 0.112 μM Evaluated anti-SARS-CoV-2 activity, showing EC50=0.112 μM Adv Sci (Weinh). 2024 Nov;11(43):e2404884
HeLa-ACE2-TMPRSS2 cells 0.20 µM Evaluated anti-SARS-CoV-2 activity with EC50 of 0.20 µM Nat Commun. 2023 Feb 25;14(1):1076
VeroE6 cells 0.11 µM Evaluated anti-SARS-CoV-2 activity with EC50 of 0.11 µM Nat Commun. 2023 Feb 25;14(1):1076
Calu-3 cells 0.078 μM Evaluated anti-SARS-CoV-2 activity, showing EC50=0.078 μM with no cytotoxicity (CC50>100 μM) Adv Sci (Weinh). 2024 Nov;11(43):e2404884

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Syrian hamsters COVID-19 hamster model Oral gavage 60 mg/kg per 12 h (120 mg/kg/day) Twice daily for 3 days To evaluate the therapeutic efficacy of S-217622 against BA.2 variants, results showed that S-217622 significantly reduced viral titers in both the upper and lower respiratory tracts of hamsters. Nature. 2022 Jul;607(7917):119-127
Syrian hamsters SARS-CoV-2 Delta variant infection model Oral 30 mg/kg and 200 mg/kg Twice a day from 0 hpi to 4 dpi Decreases viral load and ameliorates disease severity Sci Transl Med. 2023 Jan 18;15(679):eabq4064
Syrian hamsters SARS-CoV-2 infected hamster model Oral 200 mg/kg Twice daily for 5 days Evaluated the therapeutic effect of Ensitrelvir in a delayed dosing model, showing that combination therapy improved respiratory conditions and reduced pneumonia development. EBioMedicine. 2024 Jan;99:104950

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06775730 Healthy Adult Female Participa... More >>nts Less << PHASE1 RECRUITING 2025-02-27 Early Phase Clinical Unit Los ... More >>Angeles, Glendale, California, 91206, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.40mL

1.88mL

0.94mL

18.80mL

3.76mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories